https://www.selleckchem.com/products/caffeic-acid-phenethyl-ester.html 001). Through 180 days, 17 of 22 NAT+ recipients (77%) had a repeat rejection biopsy vs 12 of 28 NAT- recipients (43%) (p = 0.02). NAT+ biopsies demonstrated disparity of ACR distribution negative, low-grade, and high-grade ACR in 84%, 12%, and 4%, respectively, vs 96%, 3%, and 1%, respectively, in the NAT- group (p = 0.03). The median time to first event was 26 (interquartile range [IQR] 8-45) in the NAT+ group vs 65 (IQR 44-84) days in the NAT-. Time to first event risk model revealed that NAT+ recipients had a significantly higher rate of ACR occurrences, adjusting for demographics (p = 0.004). Transient levels of viremia contributed to higher rates and severity of ACRs. Further investigation into the mechanisms of early immune activation in NAT+ recipients is required. Transient levels of viremia contributed to higher rates and severity of ACRs. Further investigation into the mechanisms of early immune activation in NAT+ recipients is required. Lipoprotein(a) (Lp(a)) has not been well-studied in a nationally representative US cohort. The objective of this study was to investigate the distribution of Lp(a) and its associations with nonfatal cardiovascular events in a nationally representative cohort. Cross-sectional analysis using the National Health and Nutrition Examination Survey III cohort (1991-1994). We compared Lp(a) levels across demographics and tested the associations between Lp(a) and patient-reported nonfatal myocardial infarction (MI) and/or stroke using multivariate logistic regression. Median Lp(a) was 14mg/dL (interquartile range [IQR] 3, 32) (n=8214). 14.7% (95% CI 13.6%-15.9%) had Lp(a) ≥50mg/dL. Women had slightly higher median Lp(a) than men (14mg/dL [IQR 4, 33] vs 13 [(IQR 3, 30], P=.001). Non-Hispanics blacks had the highest median Lp(a) (35mg/dL [IQR 21, 64]), followed by non-Hispanic whites (12mg/dL [IQR 3, 29]) and Mexican Americans (8mg/dL [IQR1, 21]). In multivariate